KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Payables (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Payables for 17 consecutive years, with $130.3 million as the latest value for Q4 2025.

  • Quarterly Payables rose 5.51% to $130.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $130.3 million through Dec 2025, up 5.51% year-over-year, with the annual reading at $130.3 million for FY2025, 5.51% up from the prior year.
  • Payables for Q4 2025 was $130.3 million at Bio-Rad Laboratories, roughly flat from $130.1 million in the prior quarter.
  • The five-year high for Payables was $161.5 million in Q1 2023, with the low at $103.2 million in Q1 2024.
  • Average Payables over 5 years is $137.0 million, with a median of $138.6 million recorded in 2021.
  • The sharpest move saw Payables tumbled 75.75% in 2021, then skyrocketed 34.74% in 2025.
  • Over 5 years, Payables stood at $142.4 million in 2021, then decreased by 4.86% to $135.5 million in 2022, then rose by 7.08% to $145.1 million in 2023, then fell by 14.89% to $123.5 million in 2024, then rose by 5.51% to $130.3 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $130.3 million, $130.1 million, and $140.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.